C12N 2760/18211
Henipavirus
Official title: Henipavirus, e.g. hendra virus
C12N2760/18211 (Henipavirus) appears on 47 US grants and 106 published applications in this corpus.
Search patents in C12N- Granted patents
- 47
- Published applications
- 106
- Assignees
- 63
- Inventors
- 206
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 2 | 2 |
| 2011 | 1 | 2 |
| 2012 | 1 | 3 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 2 | 5 |
| 2016 | 1 | 4 |
| 2017 | 4 | 5 |
| 2018 | 4 | 3 |
| 2019 | 4 | 9 |
| 2020 | 3 | 2 |
| 2021 | 4 | 8 |
| 2022 | 5 | 8 |
| 2023 | 3 | 7 |
| 2024 | 4 | 7 |
| 2025 | 5 | 16 |
| 2026 | 2 | 15 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18222New viral proteins or individual genes, new structural or functional aspects ofIndexing code35
- C12N 2760/18234Use of virus or viral component as vaccineIndexing code29
- C12N 2760/18271Demonstrated in vivo effectIndexing code13
- C12N 2760/18251Methods of production or purification of viral materialIndexing code7
- C12N 2760/18223Virus like particles [vlp]Indexing code5
- C12N 2760/18233Use of viral protein as therapeutic agent other than vaccineIndexing code5
- C12N 2760/18221Viruses as suchIndexing code4
- C12N 2760/18232Use of virus as therapeutic agent, other than vaccineIndexing code3
All 12 subgroupsShow fewer
Recent patents
- CD8-specific antibody constructs and compositions thereof7 Jul 2026US 12,674,180 B2Sana Biotechnology, Inc.
- Paramyxovirus virus-like particles as protein delivery vehicles14 Apr 2026US 12,600,956 B2The Penn State Research Foundation
- Fusosome compositions and uses thereof5 Aug 2025US 12,378,578 B2Flagship Pioneering Innovations V, Inc.
- Vaccines against Nipah virus, and methods of using same15 Jul 2025US 12,357,683 B2The Wistar Institute of Anatomy and Biology
- Paramyxovirus virus-like particles as protein delivery vehicles1 Apr 2025US 12,264,338 B2The Penn State Research Foundation
- Universal protein g fusogens and adapter systems thereof and related lipid particles and uses24 Sep 2026US 2026/0286388 A1Sana Biotechnology, Inc.
- In vivo daric17 Sep 2026US 2026/0273058 A1Kelonia Therapeutics, Inc.
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Engineered recombinant retroviruses10 Sep 2026US 2026/0265776 A1Kelonia Therapeutics, Inc.
- Cd8-specific antibody constructs and compositions thereof10 Sep 2026US 2026/0265780 A1Sana Biotechnology, Inc.
Most cited
By later US patents
- Zoonotic disease RNA vaccines40US 11,497,807 B2ModernaTX, Inc. · 2022
- Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells11US 7,993,656 B2Allergan, Inc. · 2011
- Henipavirus vaccine9US 11,524,066 B2CureVac AG · 2022
- Nipah virus envelope pseudotyped lentiviruses and methods of their use7US 10,064,958 B2The Regents of the University of California · 2018
- Nipah virus envelope glycoprotein pseudotyped lentivirus7US 11,608,509 B2Centre National de la Recherche Scientifique (CNRS) · 2023